212 related articles for article (PubMed ID: 15615113)
1. Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?
Balemans W; Van Hul W
J Musculoskelet Neuronal Interact; 2004 Jun; 4(2):139-42. PubMed ID: 15615113
[TBL] [Abstract][Full Text] [Related]
2. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
[TBL] [Abstract][Full Text] [Related]
3. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.
van Bezooijen RL; Papapoulos SE; Löwik CW
J Endocrinol Invest; 2005; 28(8 Suppl):15-7. PubMed ID: 16323824
[TBL] [Abstract][Full Text] [Related]
4. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene.
Balemans W; Cleiren E; Siebers U; Horst J; Van Hul W
Bone; 2005 Jun; 36(6):943-7. PubMed ID: 15869924
[TBL] [Abstract][Full Text] [Related]
5. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function.
Piters E; Culha C; Moester M; Van Bezooijen R; Adriaensen D; Mueller T; Weidauer S; Jennes K; de Freitas F; Löwik C; Timmermans JP; Van Hul W; Papapoulos S
Hum Mutat; 2010 Jul; 31(7):E1526-43. PubMed ID: 20583295
[TBL] [Abstract][Full Text] [Related]
6. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
van Bezooijen RL; Svensson JP; Eefting D; Visser A; van der Horst G; Karperien M; Quax PH; Vrieling H; Papapoulos SE; ten Dijke P; Löwik CW
J Bone Miner Res; 2007 Jan; 22(1):19-28. PubMed ID: 17032150
[TBL] [Abstract][Full Text] [Related]
7. SOST is a target gene for PTH in bone.
Keller H; Kneissel M
Bone; 2005 Aug; 37(2):148-58. PubMed ID: 15946907
[TBL] [Abstract][Full Text] [Related]
8. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation.
Sutherland MK; Geoghegan JC; Yu C; Turcott E; Skonier JE; Winkler DG; Latham JA
Bone; 2004 Oct; 35(4):828-35. PubMed ID: 15454089
[TBL] [Abstract][Full Text] [Related]
9. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts.
Sutherland MK; Geoghegan JC; Yu C; Winkler DG; Latham JA
Bone; 2004 Aug; 35(2):448-54. PubMed ID: 15268896
[TBL] [Abstract][Full Text] [Related]
10. Sclerostin: a novel target for intervention in the treatment of osteoporosis.
Lewiecki EM
Discov Med; 2011 Oct; 12(65):263-73. PubMed ID: 22031665
[TBL] [Abstract][Full Text] [Related]
11. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
Sebastian A; Loots GG
Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
[TBL] [Abstract][Full Text] [Related]
12. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.
Staehling-Hampton K; Proll S; Paeper BW; Zhao L; Charmley P; Brown A; Gardner JC; Galas D; Schatzman RC; Beighton P; Papapoulos S; Hamersma H; Brunkow ME
Am J Med Genet; 2002 Jun; 110(2):144-52. PubMed ID: 12116252
[TBL] [Abstract][Full Text] [Related]
13. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.
Winkler DG; Sutherland MK; Geoghegan JC; Yu C; Hayes T; Skonier JE; Shpektor D; Jonas M; Kovacevich BR; Staehling-Hampton K; Appleby M; Brunkow ME; Latham JA
EMBO J; 2003 Dec; 22(23):6267-76. PubMed ID: 14633986
[TBL] [Abstract][Full Text] [Related]
14. Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis.
Ohyama Y; Nifuji A; Maeda Y; Amagasa T; Noda M
Endocrinology; 2004 Oct; 145(10):4685-92. PubMed ID: 15217980
[TBL] [Abstract][Full Text] [Related]
15. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
Li X; Ominsky MS; Niu QT; Sun N; Daugherty B; D'Agostin D; Kurahara C; Gao Y; Cao J; Gong J; Asuncion F; Barrero M; Warmington K; Dwyer D; Stolina M; Morony S; Sarosi I; Kostenuik PJ; Lacey DL; Simonet WS; Ke HZ; Paszty C
J Bone Miner Res; 2008 Jun; 23(6):860-9. PubMed ID: 18269310
[TBL] [Abstract][Full Text] [Related]
16. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.
ten Dijke P; Krause C; de Gorter DJ; Löwik CW; van Bezooijen RL
J Bone Joint Surg Am; 2008 Feb; 90 Suppl 1():31-5. PubMed ID: 18292354
[TBL] [Abstract][Full Text] [Related]
17. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.
van Lierop AH; Hamdy NA; Hamersma H; van Bezooijen RL; Power J; Loveridge N; Papapoulos SE
J Bone Miner Res; 2011 Dec; 26(12):2804-11. PubMed ID: 21786318
[TBL] [Abstract][Full Text] [Related]
18. Novel SOST gene mutation in a sclerosteosis patient from Morocco: a case report.
Belkhribchia MR; Collet C; Laplanche JL; Hassani R
Eur J Med Genet; 2014 Mar; 57(4):133-7. PubMed ID: 24594238
[TBL] [Abstract][Full Text] [Related]
19. [Recent topics on bone remodeling].
Shinoda Y; Ogata N; Chung UI; Kawaguchi H
Clin Calcium; 2004 Jan; 14(1):70-4. PubMed ID: 15576958
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin: current knowledge and future perspectives.
Moester MJ; Papapoulos SE; Löwik CW; van Bezooijen RL
Calcif Tissue Int; 2010 Aug; 87(2):99-107. PubMed ID: 20473488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
